Navigation Links
Titan Pharmaceuticals to Receive $3 Million Loan
Date:12/21/2009

SOUTH SAN FRANCISCO, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) today announced that it has entered into a Loan and Security Agreement with Oxford Finance Corporation ("Oxford") for a $3 million term loan. The loan will bear interest at an approximate rate of 13% per annum and be payable over three years. Under the terms of the agreement, Titan will pay Oxford an initial facility fee of $60,000 and a final payment fee of $180,000. The loan will be secured by Titan's assets and has a provision for pre-payment. Oxford will also receive five-year warrants to purchase approximately 43,000 shares at an exercise price equal to the lesser of the 10-day trailing average market price or the market price at closing.

In addition, Titan has recently received approximately $500,000 from the sale of 300,000 shares of common stock at $1.70 per share in a private placement to a single investor who participated in the company's December 2007 financing. These shares are currently restricted from trading and Titan has agreed to register the shares for resale under the Securities Act of 1933 ("Securities Act") once it has re-registered its shares under the Securities Exchange Act of 1934. The company has undertaken to file a Form 10 with the Securities and Exchange Commission ("SEC") on or prior to January 18, 2010 and to use its commercially reasonable efforts to effect such registration by April 15, 2010.

"The Board of Directors is very pleased with the progress made by the company," said Marc Rubin, MD, Executive Chairman of Titan. "Our Board members have also expressed their strong support by providing more than $500,000 in operating funds during this past few months through the exercise of options to purchase restricted shares," he added.

"This financing provides Titan with the immediate resources necessary to complete the process of becoming a reporting company again, and to
'/>"/>

SOURCE Titan Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Particle Sciences sells T-COTE(R) Line of Microfine Titanium Dioxides to Sensient
2. Titan Spine Teams Up With Syndicom, Inc. to Utilize Internationally Recognized SpineConnect Collaboration Platform
3. Not all titanium dioxide is equal when it comes to splitting water with visible light
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... ROCKVILLE, Md., Aug. 3, 2011 Neuralstem, Inc. (NYSE ... U.S. Department of Defense (DOD) contract to develop its ... cancerous brain tumors. The research contract, entitled "Research to ... be carried out in collaboration with Principal Investigator John ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Monday, August 8, 2011, after the U.S. financial markets close. ... on Monday, August 8, 2011, at 5:00 p.m. Eastern Daylight ... highlights.  A live webcast of the call will be available ...
... CAMBRIDGE, Mass., Aug. 2, 2011 Pathogenica, Inc. announced ... is speaking today at the IBC Life Sciences Drug ... During the conference, the only event on the ... development, and patient care, Dr. Doran will speak on ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week 2
(Date:8/20/2014)... have developed methods for electronically manipulating the flight muscles ... use to control those muscles. The work opens the ... for use in emergency response. , "In the big ... the movement of moths for use in applications such ... an assistant professor of electrical and computer engineering at ...
(Date:8/20/2014)... , Aug. 20, 2014  The second ... place in Tampa, Florida ... sessions with Steven Rahman, Director, Technology and Strategy at ... at Experian. The theme of this year,s event ... Privacy. "Biometrics UnPlugged: Mobility at ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Research paves way for development of cyborg moth 'biobots' 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... called ,pestilences, three are historically recognized as due to ... 19th to 21st centuries AD there were microbiological evidences ... pestis . "For a long time scholars from different ... of the past pandemics. Only ancient DNA analyses carried ...
... , May 9, 2013 Wexford Science & ... in the Wake Forest Innovation Quarter , today ... buildings currently underway represents an additional $150 million investment ... Wexford,s total investment in the Innovation Quarter to more ...
... NY and San Diego, CA A large, multi-institutional research ... a sweeping analysis in the current issue of the journal ... off to direct early human development. Led by Bing Ren ... The Salk Institute for Biological Studies and James Thomson of ...
Cached Biology News:Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 3Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3
... enables sensitive, fast and specific detection of ... Short hybridisation time ( ... spreads Multiplex capability Available with ... Probes available with different labels. ...
... Source rat adult and fetal ... $550.00, * T75 plated cells ... * This product requires Celprogen ... M55007-08 and extracellular matrix, * ...
... Isolation Kit provides a rapid method for ... from the various bacterial species found within ... of genomic DNA from both gram negative ... ,Purification is based on spin column ...
...
Biology Products: